MedTrace Logo

Clinical Evaluation of SDF Combined With KI Versus SDF in Management of Class I Carious Lesions

NCT05485272 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-08-03

No results posted yet for this study

Summary

To evaluate the clinical performance of High-Viscosity Glass Ionomer (EQUIA) versus Silver Diamine Fluoride combined with Potassium Iodide (Riva Star) and Sliver Diamine Fluoride (SDF) under High-Viscosity Glass Ionomer (EQUIA) in deep class I carious lesions, over a period of one year follow-up. The null hypothesis tested in this study, that in deep class I carious lesions, the High-Viscosity Glass Ionomer (EQUIA) versus Silver Diamine Fluoride combined with Potassium Iodide (Riva Star) and Sliver Diamine Fluoride (SDF) under High-Viscosity Glass Ionomer (EQUIA) will show the same clinical performance.

Conditions

  • Carious Lesion

Interventions

OTHER

Silver Diamine Fluoride combined with Potassium Iodide.

Riva Star, Silver diamine fluoride 38% and potassium iodide, SDI, Bayswater, Australia.

OTHER

Silver Diamine Fluoride.

A clear liquid that combines the antibacterial effects of silver and the remineralizing effects of fluoride.

OTHER

High-Viscosity Glass Ionomer.

A Glass Hybrid material.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Shorouk H Helmy · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2022-09-10
Completion
2023-03-02

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485272 on ClinicalTrials.gov